Frequently Asked Questions on the WHO Rapid Communication: key changes to the treatment of multidrug- and rifampicin-resistant TB

Overview

The Frequently Asked Questions (FAQ) and the answers proposed in this document have been prepared by the Global TB Programme of the World Health Organization (WHO), with support from the WHO Task Force to support country transition towards new recommendations for the treatment of MDR-TB. The information is provided to help Member States and implementing partners prepare for forthcoming changes following the release of the 2018 updated WHO MDR/RR-TB treatment guidelines and implementation aids. The collection of FAQs will be a “live” document and may be updated with fresh questions, answers and information should the need arise.

This publication has been updated in June 2019 with an addendum to the section “Policy-related Questions” following requests made by different TB stakeholders supporting countries making the transition to the new recommendations for the treatment of MDR-TB presented in the Consolidated Guidelines for the treatment of drug-resistant tuberculosis.